ArticleFrontiers in microbiology2020
Molecular Characterization of an IncFII
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Phenotypic and genomic characterization of tigecycline heteroresistance in carbapenem-resistantMicrobiology spectrum · 2026Article
- Molecular characterization and transmission pattern of tetracycline resistance determinants in tigecycline and carbapenem resistant Klebsiella pneumoniae isolates at a tertiary care hospital in India.Access microbiology · 2026Article
- Article
- Identification and evolution of novelMicrobiology spectrum · 2025Article
- Molecular and epidemiological characterization of carbapenem-resistant hypervirulentFrontiers in cellular and infection microbiology · 2025Article
- Epidemiological and genomic characteristics of global blaNDM-carrying Escherichia coli.Annals of clinical microbiology and antimicrobials · 2024Article
- Occurrence and mechanisms of tigecycline resistance in carbapenem- and colistin-resistant Klebsiella pneumoniae in Thailand.Scientific reports · 2024Article
- Identification of a Novel IncHI1B Plasmid in MDRAntibiotics (Basel, Switzerland) · 2022Article
- Occurrence ofAntibiotics (Basel, Switzerland) · 2022Article
- Resistance Phenotype and Molecular Epidemiology of Carbapenem-ResistantInfection and drug resistance · 2022Article
- Whole genome sequencing of Klebsiella pneumoniae clinical isolates sequence type 627 isolated from Egyptian patients.PloS one · 2022Article
- Carbapenemase ProducingAntibiotics (Basel, Switzerland) · 2021Article
- Whole-genome analyses of extended-spectrum or AmpC β-lactamase-producing Escherichia coli isolates from companion dogs in Japan.PloS one · 2021Article
- Emergence of aFrontiers in veterinary science · 2021Article
- The Plasmid-BorneFrontiers in microbiology · 2021Article
- Molecular Characterization ofFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenems and tigecycline are two important classes of antimicrobial agents to treat the infections caused by Enterobacterales. Here, we reported a plasmid carrying both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.